Staphylococcus aureus is the leading cause of death from bacteraemia worldwide, with a case fatality rate of 15 to 30% [1]. More than a third of patients develop metastatic infection, including endocarditis in about 12%, septic arthritis, vertebral osteomyelitis, spinal epidural and psoas abscesses, and seeding of implanted devices [1]. Many present with pain from one of these foci, in the back, a joint or a limb, rather than with an obvious source.
Unlike coagulase-negative staphylococci, S. aureus in a blood culture is almost never a contaminant, even when only one bottle is positive. It should be managed as a true bacteraemia until proved otherwise. Randomised evidence is thin and much of practice rests on observational studies [2, 6], but a consistent core of actions has emerged: appropriate antistaphylococcal therapy, echocardiography, a search for metastatic foci with source control, a deliberate decision on duration, and infectious diseases consultation [3].